Leukocare announces formation of Scientific Advisory Board

Martinsried/Munich, Germany, October 05, 2020

Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced the formation of a Scientific Advisory Board (SAB). The SAB works closely with the scientific management team to help grow the technology strategy portfolio of Leukocare and to advice on current and future research activities. Its members are leaders in analytical and formulation development, operating in Leukocare's core markets both the US and Europe.

Leukocare's SAB comprises of Professor Johannes Buchner, Ph.D., Technical University of Munich, Germany, Professor Paul Dalby, University College London, United Kingdom, and Professor Theodore Randolph, University of Colorado, Boulder, USA.

Dr Andreas Seidl, Chief Operating Officer at Leukocare, commented, "This is a group of highly distinguished scientific leaders with deep expertise in the field of protein folding, stabilization and formulation of therapeutic proteins as well as protein engineering. During our first board meeting, we had fruitful discussions on Leukocare's current technology portfolio and the SAB gave profound advices on how to develop it further. I am very much looking forward to continue working with Johannes, Paul and Theodore."

Professor Johannes Buchner, Ph.D. is Professor and Chair Biotechnology at the Technical University of Munich, Germany. His research interests include principals of the structural formation of proteins, state-of-the-art analytical tools to understand protein folding, cellular machinery of protein folding as well as understanding the biosynthesis and folding of antibodies as basis for large-scale production in biotechnological processes. Johannes received several prizes for his work, including the Hans Neurath Award, the Kossel-Award, the Max Bergmann Medal, and the Schleiden Medal. He has authored 275 publications in peer-reviewed journals.

Professor Paul Dalby is Director of the EPSRC Centre for Doctoral Training in Emergent Macromolecular Therapies, Co-Director of the EPSRC Future Targeted Healthcare Manufacturing Hub, and Deputy Head of the Department of Biochemical Engineering at University College London, United Kingdom. He also chairs the Biotechnology Group of the Royal Society of Chemistry. His research focuses on routes to improve therapeutic proteins for ease of manufacture, formulation and delivery to patients. He combines protein engineering and formulation, with biophysical characterization, molecular modelling and simulation, to understand the factors that influence protein stability, and to guide protein engineering and

formulation for improved properties. Paul Dalby has authored over 90 publications in peer-reviewed journals.

Professor Theodore Randolph has more than 30 years of experience in Pharmaceutical Biotechnology. He is professor of Chemical and Biological Engineering and Co-Director of the Center for Pharmaceutical Biotechnology at the University of Colorado, Boulder, USA. His research interests focus on “Converting Molecules into Drugs”: application of biophysical methods for formulation development, aggregation & immunogenicity of protein therapeutics, and stability of protein-based vaccines. He has published more than 240 scientific articles in peer-reviewed journals, is an inventor on 28 U.S. patents and has been rewarded numerous research awards including American Pharmacists Association Ebert Award, the AIChE Professional Progress Award and the National Science Foundation Presidential Young Investigator Award.

About Leukocare AG

Leukocare AG, located in Martinsried/Munich, Germany, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence.

The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product’s needs.

Leukocare’s superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

www.leukocare.com

Contact:
Michael Scholl
CEO
michael.scholl@leukocare.com
+49 (0) 89 7801 6650

Rebekka Ströver
Specialist Communications & Marketing
rebekka.stroever@leukocare.com
+ 49 (0) 89 7801 665 14